The Rs 4,326-crore IPO, which was subscribed 15.3 times, was one of the biggest by a domestic drug maker since Gland Pharma came up with a Rs 6,480-crore issue in 2020 and the biggest of 2023, so far
The Rs 4,326-crore IPO, which was subscribed 15.3 times, was one of the biggest by a domestic drug maker since Gland Pharma came up with a Rs 6,480-crore issue in 2020 and the biggest of 2023, so far The Rs 4,326-crore IPO, which was subscribed 15.3 times, was one of the biggest by a domestic drug maker since Gland Pharma came up with a Rs 6,480-crore issue in 2020 and the biggest of 2023, so far Moneycontrol Latest News Read More
हिन्दी 
English